Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
October 03, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
August 23, 2023 17:08 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
August 14, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment...
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
July 10, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 24, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
May 22, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
May 12, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in...
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
March 30, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
March 27, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...